Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System

Andreone, 2014, ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection, Gastroenterology, 147, 359, 10.1053/j.gastro.2014.04.045

Ferenci, 2014, ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV, N Engl J Med, 370, 1983, 10.1056/NEJMoa1402338

Kowdley, 2014, Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis, N Engl J Med, 370, 1879, 10.1056/NEJMoa1402355

Poordad, 2014, ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis, N Engl J Med, 370, 1973, 10.1056/NEJMoa1402869

Zeuzem, 2014, Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin, N Engl J Med, 370, 1604, 10.1056/NEJMoa1401561

Afdhal, 2014, Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection, N Engl J Med, 370, 1483, 10.1056/NEJMoa1316366

Afdhal, 2014, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N Engl J Med, 370, 1889, 10.1056/NEJMoa1402454

Feld, 2014, Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin, N Engl J Med, 370, 1594, 10.1056/NEJMoa1315722

Naggie, 2015, Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1, N Engl J Med, 373, 705, 10.1056/NEJMoa1501315

Charlton, 2015, Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease, Gastroenterology, 149, 649, 10.1053/j.gastro.2015.05.010

Gane, 2015, Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection, Gastroenterology, 149, 1454, 10.1053/j.gastro.2015.07.063

Beste, 2015, Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients, Eur J Gastroenterol Hepatol, 27, 123, 10.1097/MEG.0000000000000241

Ioannou, 2014, Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans, Clin Gastroenterol Hepatol, 12, 1371, 10.1016/j.cgh.2013.12.011

Backus, 2007, Predictors of response of US veterans to treatment for the hepatitis C virus, Hepatology, 46, 37, 10.1002/hep.21662

Beste, 2015, Prevalence and treatment of chronic hepatitis C Virus infection in the US Department of Veterans Affairs, Epidemiol Rev, 37, 131, 10.1093/epirev/mxu002

Ioannou, 2013, Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients, Aliment Pharmacol Ther, 38, 1373, 10.1111/apt.12524

Sterling, 2015, Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir, Aliment Pharmacol Ther, 41, 671, 10.1111/apt.13095

US Department of Veterans Affairs. Health services research and development. http://www.hsrd.research.va.gov/for_researchers/vinci/cdw.cfm. Accessed February 10, 2016.

Kramer, 2005, The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in US veterans with hepatitis C, Am J Gastroenterol, 100, 56, 10.1111/j.1572-0241.2005.40670.x

Ioannou, 2007, Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis, Clin Gastroenterol Hepatol, 5, 938, 10.1016/j.cgh.2007.02.039

Davila, 2011, Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States, Ann Intern Med, 154, 85, 10.7326/0003-4819-154-2-201101180-00006

Ioannou, 2013, The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection, Hepatology, 57, 249, 10.1002/hep.25800

Kramer, 2008, The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases, Aliment Pharmacol Ther, 27, 274, 10.1111/j.1365-2036.2007.03572.x

Beste, 2015, Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US Veterans, 2001–2013, Gastroenterology, 149, 1471, 10.1053/j.gastro.2015.07.056

Kramer, 2011, Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study, Am J Gastroenterol, 106, 483, 10.1038/ajg.2010.430

Beste, 2010, Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication, Clin Gastroenterol Hepatol, 8, 972, 10.1016/j.cgh.2010.07.012

Kanwal, 2011, Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection, Gastroenterology, 140, 1182, 10.1053/j.gastro.2010.12.032

Miller, 2004, Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data, Diabetes Care, 27, B10, 10.2337/diacare.27.suppl_2.B10

Vallet-Pichard, 2007, FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest, Hepatology, 46, 32, 10.1002/hep.21669

Yoshida, 2015, Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus, Hepatology, 61, 41, 10.1002/hep.27366

McCaffrey, 2013, A tutorial on propensity score estimation for multiple treatments using generalized boosted models, Stat Med, 32, 3388, 10.1002/sim.5753

HCV Guidance: recommendations for testing, managing, and treating hepatitis C. AASLD and IDSA. Available at: http://www.hcvguidelines.org. Accessed January 25, 2016.

Harvoni Package Insert. Available at: https://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed January 26, 2016.

Chronic hepatitis C virus (HCV) infection: treatment considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and National Viral Hepatitis Program. Available at: http://www.hepatitis.va.gov/provider/index.asp. Accessed January 26, 2016.

Brown, 2016, Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network, Liver Transpl, 22, 24, 10.1002/lt.24366

Sulkowski, 2016, Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection, Gastroenterology, 150, 419, 10.1053/j.gastro.2015.10.013

Foster, 2016, Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis, J Hepatol, 64, 1224, 10.1016/j.jhep.2016.01.029

Backus, 2016, Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive genotype 1 hepatitis C infected patients, Hepatology, 10.1002/hep.28625

Nezam A, Bacon BR, Dieterich DT, et al. Failure with all-oral regimens: academic and community treatment of a real-world population from the TRIO Network. The Liver Meeting 2015, Late Breaking Abstract 17, November 16, 2015, The Liver Meeting, San Francisco, CA.2016.